

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### SECTION 1. IDENTIFICATION

Product name : Milbemycin Oxime / Lufenuron Formulation

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product  
Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

##### Hazards for the product as supplied

Skin sensitization : Category 1  
Reproductive toxicity : Category 1B  
Specific target organ toxicity : Category 1 (Central nervous system)  
- repeated exposure  
Specific target organ toxicity : Category 1 (Central nervous system, Lungs, Liver, Stomach)  
- repeated exposure (Oral)

##### Other hazards

None known.

##### GHS label elements

Hazard pictograms :

Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.  
H360D May damage the unborn child.  
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure.  
H372 Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P261 Avoid breathing dust, fume, gas, mist, vapors or spray.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing must not be allowed out of the workplace.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of water.  
P308 + P313 IF exposed or concerned: Get medical attention.  
P333 + P313 If skin irritation or rash occurs: Get medical attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Storage:**  
P405 Store locked up.

**Disposal:**  
P501 Dispose of contents and container to an approved waste disposal plant.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

| Chemical name       | CAS No./Unique ID | Concentration (% w/w) | Trade secret |
|---------------------|-------------------|-----------------------|--------------|
| Lufenuron (ISO)     | 103055-07-8*      | >= 15 - <= 40         | TSC          |
| Polyethylene glycol | 25322-68-3*       | >= 10 - <= 30         | TSC          |
| Cellulose           | 9004-34-6*        | >= 10 - <= 30         | TSC          |
| Starch              | 9005-25-8*        | >= 3 - <= 7           | TSC          |
| Milbemycin Oxime    | 129496-10-2*      | >= 1 - <= 5           | TSC          |

\* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

- If inhaled : When symptoms persist or in all cases of doubt seek medical advice.  
: If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.  
May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure.  
No information available.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
- 

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing. Avoid breathing dust, fume, gas, mist, vapors or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

---

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

| Components                | CAS-No.     | Value type<br>(Form of exposure) | Control parameters / Permissible concentration | Basis     |
|---------------------------|-------------|----------------------------------|--|-----------|
| Lufenuron (ISO)           | 103055-07-8 | TWA                              | 200 µg/m <sup>3</sup> (OEB 2)                  | Internal  |
| Further information: DSEN |             |                                  |  |           |
|                           |             | Wipe limit                       | 100 µg/100 cm <sup>2</sup>                     | Internal  |
| Polyethylene glycol       | 25322-68-3  | TWA (aerosol)                    | 10 mg/m <sup>3</sup>                           | US WEEL   |
| Cellulose                 | 9004-34-6   | TWA                              | 10 mg/m <sup>3</sup>                           | ACGIH     |
|                           |             | TWA (Respirable)                 | 5 mg/m <sup>3</sup>                            | NIOSH REL |
|                           |             | TWA (total)                      | 10 mg/m <sup>3</sup>                           | NIOSH REL |
|                           |             | TWA (total dust)                 | 15 mg/m <sup>3</sup>                           | OSHA Z-1  |
|                           |             | TWA (respirable fraction)        | 5 mg/m <sup>3</sup>                            | OSHA Z-1  |
| Starch                    | 9005-25-8   | TWA                              | 10 mg/m <sup>3</sup>                           | ACGIH     |
|                           |             | TWA (Respirable)                 | 5 mg/m <sup>3</sup>                            | NIOSH REL |
|                           |             | TWA (total)                      | 10 mg/m <sup>3</sup>                           | NIOSH REL |
|                           |             | TWA (total dust)                 | 15 mg/m <sup>3</sup>                           | OSHA Z-1  |
|                           |             | TWA (respirable fraction)        | 5 mg/m <sup>3</sup>                            | OSHA Z-1  |
| Milbemycin Oxime          | 129496-10-2 | TWA                              | 0.1 mg/m <sup>3</sup> (OEB2)                   | Internal  |

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**  
**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 06/20/2025  |
| 4.2     | 12/08/2025     | 6365226-00014 | Date of first issue: 09/21/2020 |

Skin and body protection : Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hygiene measures : Work uniform or laboratory coat.

: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

|  |   |                   |
|--|---|-------------------|
| Appearance                                       | : | solid             |
| Color  | : | brown             |
| Odor   | : | odorless          |
| Odor Threshold                                   | : | No data available |
| pH   | : | No data available |
| Melting point/freezing point                     | : | No data available |
| Initial boiling point and boiling range          | : | No data available |
| Flash point                                      | : | Not applicable    |
| Evaporation rate                                 | : | Not applicable    |
| Flammability (solid, gas)                        | : | No data available |
| Flammability (liquids)                           | : | Not applicable    |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapor pressure                                   | : | Not applicable    |
| Relative vapor density                           | : | Not applicable    |
| Relative density                                 | : | No data available |

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

Density : No data available

Solubility(ies)  
Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### **Product:**

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 75 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

---

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

### **Components:**

#### **Lufenuron (ISO):**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): 2,350 mg/m<sup>3</sup>  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Polyethylene glycol:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: Based on data from similar materials

#### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Starch:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Milbemycin Oxime:**

Acute oral toxicity : LD50 (Rat): 532 - 863 mg/kg  
LD50 (Mouse): 722 - 946 mg/kg

Acute inhalation toxicity : LC50 (Rat): 1,200 mg/m<sup>3</sup>  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### **Lufenuron (ISO):**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

##### **Polyethylene glycol:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

##### **Milbemycin Oxime:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Lufenuron (ISO):**

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

##### **Polyethylene glycol:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials

##### **Starch:**

Species : Rabbit  
Result : No eye irritation

##### **Milbemycin Oxime:**

Species : Rabbit  
Result : No eye irritation

### Respiratory or skin sensitization

#### **Skin sensitization**

May cause an allergic skin reaction.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### Respiratory sensitization

Not classified based on available information.

#### Components:

##### **Lufenuron (ISO):**

Test Type : Maximization Test  
Species : Guinea pig  
Assessment : May cause sensitization by skin contact.  
Result : Sensitizer

##### **Polyethylene glycol:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

##### **Starch:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

##### **Milbemycin Oxime:**

Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### **Lufenuron (ISO):**

Genotoxicity in vitro : Test Type: Ames test  
Result: negative

Test Type: Mouse Lymphoma  
Test system: Chinese hamster cells  
Result: negative

Test Type: Cytogenetic assay  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: rat hepatocytes  
Result: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

- Genotoxicity in vivo : Test system: Human lymphocytes  
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Result: negative
- Genotoxicity in vivo : Test Type: Unscheduled DNA synthesis test (UDS) in testicular cells  
Species: Rat  
Result: negative
- Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.
- Polyethylene glycol:**  
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials
- Cellulose:**  
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative
- Genotoxicity in vivo : Test Type: In vitro mammalian cell gene mutation test  
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative
- Starch:**  
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative
- Milbemycin Oxime:**  
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative
- Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: negative
- Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Result: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Lufenuron (ISO):**

Species : Rat  
Application Route : Ingestion  
Exposure time : 18 month(s)  
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

#### **Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### **Reproductive toxicity**

May damage the unborn child.

### **Components:**

#### **Lufenuron (ISO):**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity Parent: NOAEL: 8.3 mg/kg wet weight  
Early Embryonic Development: NOAEL: 20.9 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 500 mg/kg body weight  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Symptoms: No adverse effects.  
Remarks: No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
Species: Rat

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

Application Route: Ingestion  
General Toxicity Maternal: NOAEL: 20.9 mg/kg body weight  
Embryo-fetal toxicity.: 8.3 mg/kg body weight  
Result: Fetal abnormalities.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

### **Milbemycin Oxime:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Dog  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative

Test Type: Embryo-fetal development  
Species: Dog  
Application Route: Ingestion  
Result: negative

### **STOT-single exposure**

Not classified based on available information.

### **Components:**

#### **Lufenuron (ISO):**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### **STOT-repeated exposure**

Causes damage to organs (Central nervous system) through prolonged or repeated exposure.  
Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.

### **Components:**

#### **Lufenuron (ISO):**

Routes of exposure : Oral  
Target Organs : Central nervous system, Lungs, Liver, Stomach  
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

#### **Milbemycin Oxime:**

Routes of exposure : Ingestion  
Target Organs : Central nervous system  
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

### **Repeated dose toxicity**

### **Components:**

#### **Lufenuron (ISO):**

Species : Rat  
NOAEL : 5.34 mg/kg  
Application Route : oral (feed)  
Exposure time : 4 Months  
Target Organs : Central nervous system, digestive system  
Symptoms : central nervous system effects

Species : Rat  
NOAEL : 1.93 mg/kg  
Application Route : oral (feed)  
Exposure time : 2 y  
Symptoms : central nervous system effects, Convulsions

Species : Mouse  
NOAEL : 2.12 mg/kg  
Application Route : oral (feed)  
Exposure time : 18 Months  
Target Organs : Central nervous system, Liver, Prostate  
Symptoms : central nervous system effects, Convulsions

Species : Dog  
NOAEL : 7.02 mg/kg  
Application Route : oral (feed)  
Exposure time : 1 y  
Target Organs : Central nervous system, Liver, Lungs  
Symptoms : Convulsions, Fatality, Irregularities

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### Cellulose:

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

### Starch:

Species : Rat  
NOAEL :  $\geq 2,000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

### Milbemycin Oxime:

Species : Rat  
NOAEL : 3 mg/kg  
LOAEL : 15 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Symptoms : Liver disorders, Blood disorders

Species : Dog  
LOAEL : 8.6 mg/kg  
Application Route : Ingestion  
Exposure time : 3 Days  
Symptoms : Tremors

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Lufenuron (ISO):

General Information : Remarks: May be harmful if swallowed.  
May cause neurotoxic effects.

#### Milbemycin Oxime:

Ingestion : Symptoms: Salivation, Convulsions, Diarrhea, Weakness,  
Vomiting, Tremors, Coma  
Remarks: Based on Animal Evidence

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### Lufenuron (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)):  $> 73,100$   $\mu\text{g/l}$   
Exposure time: 96 h

---

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 06/20/2025  |
| 4.2     | 12/08/2025     | 6365226-00014 | Date of first issue: 09/21/2020 |

---

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): > 29,000 µg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 370 µg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0.042 µg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035

EC50 (Daphnia magna (Water flea)): 0.41 µg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Raphidocelis subcapitata (freshwater green alga)): 209 µg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

EC50 (Scenedesmus subspicatus): 17 µg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 80 µg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (Oncorhynchus mykiss (rainbow trout)): 20 µg/l  
Exposure time: 359 d  
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 8.38 µg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

NOEC (Daphnia magna (Water flea)): 90 µg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

NOEC (Chironomus riparius (harlequin fly)): 2 µg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

### Polyethylene glycol:

Toxicity to fish : LC50 (Poecilia reticulata (guppy)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

### Milbemycin Oxime:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): 0.16 µg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 0.03 µg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 87 µg/l  
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.01 µg/l

### Persistence and degradability

#### Components:

#### **Polyethylene glycol:**

Biodegradability : Result: rapidly degradable  
Remarks: Based on data from similar materials

#### **Cellulose:**

Biodegradability : Result: Readily biodegradable.

### Bioaccumulative potential

#### Components:

#### **Lufenuron (ISO):**

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)  
Bioconcentration factor (BCF): 28  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 5.12

#### **Polyethylene glycol:**

Partition coefficient: n-octanol/water : log Pow: < 3

#### **Milbemycin Oxime:**

Bioaccumulation : Bioconcentration factor (BCF): 440

Partition coefficient: n-octanol/water : log Pow: 7

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

---

### Mobility in soil

#### Components:

#### Lufenuron (ISO):

Distribution among environmental compartments : log Koc: 5.38  
Method: OECD Test Guideline 106

#### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

#### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

#### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III

---

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 06/20/2025  |
| 4.2     | 12/08/2025     | 6365226-00014 | Date of first issue: 09/21/2020 |

---

Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

UN/ID/NA number : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Milbemycin Oxime, Lufenuron (ISO))  
Class : 9  
Packing group : III  
Labels : CLASS 9  
ERG Code : 171  
Marine pollutant : yes(Milbemycin Oxime, Lufenuron (ISO))  
Remarks : Above applies only to containers over 119 gallons (450 liters)  
in case of liquids, or 882 lbs. (400 kg) in case of solids.  
Above applies only to containers over 119 gallons (450 liters)  
in case of liquids, or 882 lbs. (400 kg) in case of solids.  
Shipment by ground under DOT is non-regulated; however it  
may be shipped per the applicable hazard classification to  
facilitate multi-modal transport involving ICAO (IATA) or IMO.

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Respiratory or skin sensitization  
Reproductive toxicity  
Specific target organ toxicity (single or repeated exposure)

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

### Pennsylvania Right To Know

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

Version 4.2      Revision Date: 12/08/2025      SDS Number: 6365226-00014      Date of last issue: 06/20/2025  
Date of first issue: 09/21/2020

|   |             |
|---|-------------|
| Lufenuron (ISO)                                   | 103055-07-8 |
| Polyethylene glycol                               | 25322-68-3  |
| Cellulose   | 9004-34-6   |
| D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate | 64044-51-5  |
| Starch  | 9005-25-8   |

### California Permissible Exposure Limits for Chemical Contaminants

|           |           |
|-----------|-----------|
| Cellulose | 9004-34-6 |
| Starch    | 9005-25-8 |

### The ingredients of this product are reported in the following inventories:

AICS : not determined


CA. DSL : not determined

IECSC : not determined

## SECTION 16. OTHER INFORMATION

### Further information

#### NFPA 704:



#### HMIS® IV:

|                 |   |   |
|-----------------|---|---|
| HEALTH          | * | 3 |
| FLAMMABILITY    |   | 1 |
| PHYSICAL HAZARD |   | 0 |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
NIOSH REL : USA. NIOSH Recommended Exposure Limits  
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants  
US WEEL : USA. Workplace Environmental Exposure Levels (WEEL)  
ACGIH / TWA : 8-hour, time-weighted average  
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek  
OSHA Z-1 / TWA : 8-hour time weighted average  
US WEEL / TWA : 8-hr TWA

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Milbemycin Oxime / Lufenuron Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 06/20/2025  |
| 4.2     | 12/08/2025     | 6365226-00014 | Date of first issue: 09/21/2020 |

---

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 12/08/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8